Clear market notes built around the JSE, the rand, and what matters locally.

2026-07-20 14:28 • The Motley Fool Negative Axe Cap view: Selective

In a comparison of two major oil giants, ExxonMobil emerges as the superior investment choice over Chevron. While both companies offer attractive dividends, ExxonMobil demonstrates stronger fundamentals with a larger market cap ($611B vs $366B), superior stock performance (150% vs 90% over five years), and better cash generation. Chevron faces headwinds including negative free cash flow in Q1 2026, legal issues, geopolitical risks in Venezuela, and ongoing restructuring from its Hess acquisition, whereas ExxonMobil plans $20 billion in share buybacks for 2026.

Axe note: Chevron's challenges reveal why ExxonMobil is the better energy play for JSE-linked portfolios.

2026-07-20 14:23 • The Motley Fool Positive Axe Cap view: Selective

Chipotle Mexican Grill's stock has declined 36% over the past year due to sluggish sales growth and rising costs, but the author argues this presents a buying opportunity. With the P/E ratio compressed from 45 to 31 and improved valuation metrics, the stock could rebound once economic pressures ease and consumer spending recovers. The slowdown appears cyclical rather than company-specific, with increased restaurant visits suggesting continued customer interest.

Axe note: Chipotle’s share price has fallen sharply, but a recovery in consumer spending could restore its growth story.

2026-07-20 14:17 • The Motley Fool Positive Axe Cap view: Selective

The article compares two healthcare ETFs: Invesco Pharmaceuticals ETF (PJP), which focuses on concentrated U.S. pharma exposure with 29 holdings, and iShares Global Healthcare ETF (IXJ), which offers diversified global healthcare with 110 holdings. PJP delivered superior 1-year returns of 44.90% versus IXJ's 18.20%, though IXJ has a lower expense ratio (0.40% vs 0.57%) and higher dividend yield (1.50% vs 0.90%). The article recommends PJP for investors seeking healthcare exposure due to its stronger performance across most timeframes.

Axe note: Invesco’s focused pharma ETF outperforms the broader iShares global healthcare fund, but local investors should weigh concentration risks and rand impact.